President @RTErdogan, who is in New York for the 81st session of the United Nations General Assembly, received Dr. Patrick Soon-Shiong at the Turkish House.

@anktivaoffical is a SCAM beware of fraud. Impersonating Anktiva. You can not get Anktiva shipped to your house. You can not setup a consult with Dr. Pat for $799 via PayPal or zelle. Beware!!!

What if the next breakthrough in solid-tumor CAR-T isn’t simply finding a better target—but building a T cell that can sustain itself after entering the tumor? A new report in the New England Journal of Medicine describes a remarkable case: a 3-year-old boy with chemotherapy-resistant metastatic hepatoblastoma achieved complete tumor regression lasting at least 12 months after two infusions of glypican-3–specific CAR-T cells. What made these CAR-T cells different? They were engineered to coexpress interleukin-15 (IL-15) and interleukin-21 (IL-21). These cytokines are intended to enhance the persistence, proliferation, and functional fitness of the infused T cells—potentially helping them overcome some of the barriers that have limited CAR-T activity in solid tumors. And the clinical result is striking: 🧬 Glypican-3–targeted CAR-T 🔬 IL-15 + IL-21 coexpression 👦 3-year-old with chemotherapy-resistant metastatic hepatoblastoma 🎯 Complete regression ⏳ Response sustained ≥12 months This is only a single patient report, so it is far too early to draw conclusions about efficacy across hepatoblastoma or other solid tumors. But the concept is important. For years, much of CAR-T engineering has focused on the receptor: What should the T cell recognize? Increasingly, the question is becoming: What does the T cell need to survive, expand, and remain functional once it reaches the tumor? Cytokine-armored CAR-T cells represent one approach to that problem. This case provides an intriguing glimpse of what may be possible when we engineer not only what CAR-T cells see, but also how they behave once they get there. Solid tumors remain one of the biggest frontiers for cellular therapy. And sometimes, a single patient can show the field what might be possible next. nejm.org/doi/full/10.1056/NE…

Last round of treatment yesterday at ImmunityBio. ❤️ I’ve been incredibly fortunate to participate in a single-patient investigational new drug (IND) protocol with the goal of reducing my risk of colon cancer recurrence after my extended right hemicolectomy surgery last year. There is so much potential in these immune-based protocols, and I hope every day for positive study results and ultimately, access for anyone who may benefit from them. The best news: my latest bloodwork showed a very low CEA, and my Signatera test showed ZERO detectable circulating tumor DNA. 🙏🏼 My next big milestone is March: two years from surgery with no recurrence. For now, I’m feeling strong, grateful, and hopeful—and confident that my immune system is alert and ready for whatever comes next. 💪🏼 #whatsyourALC #immunitybio #coloncancer

We're producing cancer-fighting isotopes, imaging and testing critical aerospace components, enabling next-gen fusion research and building toward clean energy. Want to see where it all happens? #OnWisconsin #fusion #cleanenergy #isotopes #wisconsin #janesville #fitchburg